|
1.
|
Tamura M, Gu J, Matsumoto K, Aota S,
Parsons R and Yamada KM: Inhibition of cell migration, spreading,
and focal adhesions by tumor suppressor PTEN. Science.
280:1614–1617. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Waite KA and Eng C: Protean PTEN: form and
function. Am J Hum Genet. 70:829–844. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Lu Y, Lin YZ, LaPushin R, Cuevas B, Fang
X, Yu SX, Davies MA, Khan H, Furui T, Mao M, Zinner R, Hung MC,
Steck P, Siminovitch K and Mills GB: The PTEN/MMAC1/TEP tumor
suppressor gene decreases cell growth and induces apoptosis and
anoikis in breast cancer cells. Oncogene. 18:7034–7045. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Weng LP, Brown JL and Eng C: PTEN
coordinates (G1) arrest by down-regulating cyclin D1 via its
protein phosphatase activity and up-regulating p27 via its lipid
phosphatase activity in a breast cancer model. Hum Mol Genet.
10:599–604. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Tamguney T and Stokoe D: New insights into
PTEN. J Cell Sci. 120:4071–4079. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Marsh DJ, Coulon V, Lunetta KL,
Rocca-Serra P, Dahia PL, Zheng Z, Liaw D, Caron S, Duboué B, Lin
AY, Richardson AL, Bonnetblanc JM, Bressieux JM, Cabarrot-Moreau A,
Chompret A, Demange L, Eeles RA, Yahanda AM, Fearon ER, Fricker JP,
Gorlin RJ, Hodgson SV, Huson S, Lacombe D, Eng C, et al: Mutation
spectrum and genotype-phenotype analyses in Cowden disease and
Bannayan-Zonana syndrome, two hamartoma syndromes with germline
PTEN mutation. Hum Mol Genet. 7:507–515. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Baeza N, Weller M, Yonekawa Y, Kleihues P
and Ohgaki H: PTEN methylation and expression in glioblastomas.
Acta Neuropathol. 106:479–485. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Freihoff D, Kempe A, Beste B,
Wappenschmidt B, Kreyer E, Hayashi Y, Meindl A, Krebs D, Wiestler
OD, von Deimling A and Schmutzler RK: Exclusion of a major role for
the PTEN tumour-suppressor gene in breast carcinomas. Br J Cancer.
79:754–758. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Bose S, Wang SI, Terry MB, Hibshoosh H and
Parsons R: Allelic loss of chromosome 10q23 is associated with
tumor progression in breast carcinomas. Oncogene. 17:123–127. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Garcia JM, Silva JM, Dominguez G, Gonzalez
R, Navarro A, Carretero L, Provencio M, España P and Bonilla F:
Allelic loss of the PTEN region (10q23) in breast carcinomas of
poor pathophenotype. Breast Cancer Res Treat. 57:237–243. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Perren A, Weng LP, Boag AH, Ziebold U,
Thakore K, Dahia PL, Komminoth P, Lees JA, Mulligan LM, Mutter GL
and Eng C: Immunohistochemical evidence of loss of PTEN expression
in primary ductal adenocarcinomas of the breast. Am J Pathol.
155:1253–1260. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Bose S, Crane A, Hibshoosh H, Mansukhani
M, Sandweis L and Parsons R: Reduced expression of PTEN correlates
with breast cancer progression. Hum Pathol. 33:405–409. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Depowski PL, Rosenthal SI and Ross JS:
Loss of expression of the PTEN gene protein product is associated
with poor outcome in breast cancer. Mod Pathol. 14:672–676. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Lee JS, Kim HS, Kim YB, Lee MC, Park CS
and Min KW: Reduced PTEN expression is associated with poor outcome
and angiogenesis in invasive ductal carcinoma of the breast. Appl
Immunohistochem Mol Morphol. 12:205–210. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Shoman N, Klassen S, McFadden A, Bickis
MG, Torlakovic E and Chibbar R: Reduced PTEN expression predicts
relapse in patients with breast carcinoma treated by tamoxifen. Mod
Pathol. 18:250–259. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Campbell RA, Bhat-Nakshatri P, Patel NM,
Constantinidou D, Ali S and Nakshatri H: Phosphatidylinositol
3-kinase/AKT-mediated activation of estrogen receptor alpha: a new
model for anti-estrogen resistance. J Biol Chem. 276:9817–9824.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Keshet I, Lieman-Hurwitz J and Cedar H:
DNA methylation affects the formation of active chromatin. Cell.
44:535–543. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Antequera F: Structure, function and
evolution of CpG island promoters. Cell Mol Life Sci. 60:1647–1658.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Soria JC, Lee HY, Lee JI, Wang L, Issa JP,
Kemp BL, Liu DD, Kurie JM, Mao L and Khuri FR: Lack of PTEN
expression in non-small cell lung cancer could be related to
promoter methylation. Clin Cancer Res. 8:1178–1184. 2002.PubMed/NCBI
|
|
20.
|
Khan S, Kumagai T, Vora J, Bose N, Sehgal
I, Koeffler PH and Bose S: PTEN promoter is methylated in a
proportion of invasive breast cancers. Int J Cancer. 112:407–410.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Shaw RJ and Cantley LC: Ras, PI(3)K and
mTOR signalling controls tumour cell growth. Nature. 441:424–430.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Janzen V and Scadden DT: Stem cells: good,
bad and reformable. Nature. 441:418–419. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Simpson L and Parsons R: PTEN: life as a
tumor suppressor. Exp Cell Res. 264:29–41. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Dudek H, Datta SR, Franke TF, Birnbaum MJ,
Yao R, Cooper GM, Segal RA, Kaplan DR and Greenberg ME: Regulation
of neuronal survival by the serine-threonine protein kinase Akt.
Science. 275:661–665. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Ramaswamy S, Nakamura N, Vazquez F, Batt
DB, Perera S, Roberts TM and Sellers WR: Regulation of G1
progression by the PTEN tumor suppressor protein is linked to
inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc
Natl Acad Sci USA. 96:2110–2115. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Stahl JM, Sharma A, Cheung M, Zimmerman M,
Cheng JQ, Bosenberg MW, Kester M, Sandirasegarane L and Robertson
GP: Deregulated Akt3 activity promotes development of malignant
melanoma. Cancer Res. 64:7002–7010. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Curtin JA, Fridlyand J, Kageshita T, Patel
HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE,
Pinkel D and Bastian BC: Distinct sets of genetic alterations in
melanoma. N Engl J Med. 353:2135–2147. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Lian Z and Di Cristofano A: Class reunion:
PTEN joins the nuclear crew. Oncogene. 24:7394–7400. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Miller TW, Pérez-Torres M, Narasanna A,
Guix M, Stål O, Pérez-Tenorio G, Gonzalez-Angulo AM, Hennessy BT,
Mills GB, Kennedy JP, Lindsley CW and Arteaga CL: Loss of
phosphatase and tensin homologue deleted on chromosome 10 engages
ErbB3 and insulin-like growth factor-I receptor signaling to
promote antiestrogen resistance in breast cancer. Cancer Res.
69:4192–4201. 2009. View Article : Google Scholar
|
|
30.
|
Saal LH, Johansson P, Holm K,
Gruvberger-Saal SK, She QB, Maurer M, Koujak S, Ferrando AA,
Malmström P, Memeo L, Isola J, Bendahl PO, Rosen N, Hibshoosh H,
Ringnér M, Borg A and Parsons R: Poor prognosis in carcinoma is
associated with a gene expression signature of aberrant PTEN tumor
suppressor pathway activity. Proc Natl Acad Sci USA. 104:7564–7569.
2007. View Article : Google Scholar : PubMed/NCBI
|
